Cells were prepared in lysis buffer containing 50 mM HEPES (pH 7.2), 150 mM NaCl, 25 mM beta-glycerophosphate, 25 mM NaF, 5 mM EGTA, 1 mM EDTA, 1% NP-40, 1 mM sodium orthovanadate, 0.1 mM PMSF, and a Protease Inhibitor cocktail (leupeptin, pepstatin, aprotinin, and antipain; each 5 μg/ml). For secretory protein preparation, the culture medium was centrifuged, and cellular components and debris were discarded. The culture medium was concentrated using 10 K cut-off microcon (Amicon), or by adding ice-cold acetone, the precipitated protein was resuspended in lysis buffer. The proteins were separated on SDS-PAGE and transferred to a 0.45-μm
Immobilon P-transfer membrane (Millipore). The membrane was blocked in 5% (w/v) non-fat milk and then probed with a primary antibody; anti-human GLRX3 antibody,
beta-catenin,
E-cadherin,
GAPDH (Santacruz, Dallas, Texas, US),
c-MET, PI3K,
pAKT (Cell signaling, Danvers, Massachusetts, US), AKT, Wnt1, 3, 5a, 7b,11, 16, RhoA, RhoB,
pJNK, RAC1, Dvl2 (Santacruz, Dallas, Texas, US), and
ABCG2 (Abcam, Cambridge, UK). The immunoreactive material was then visualized using
SuperSignal West Pico Chemiluminescent substrate (Pierce Biotechnology, Rockford, Illinois, US) according to the manufacturer’s instructions.
Jo J.H., Kim S.A., Lee J.H., Park Y.R., Kim C., Park S.B., Jung D.E., Lee H.S., Chung M.J, & Song S.Y. (2021). GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. BMC Cancer, 21, 1241.